On the recordMay 15, 2019
Basically Gilead is going to reap the benefit of two periods of exclusivity rather than one, correct?
Source
congress.govEditor's note · Context
Sarbanes highlights potential exclusivity benefits for Gilead from two drug developments.
Share
More from John Sarbanes
Dec 4, 2024
I certainly support this legislation to pay tribute to the giant Elijah Cummings. I have so many memories of Elijah. The first memory I have is that we both represented Baltimore for many years together. I started to notice that he and I…
Jun 20, 2023
I was unable to vote today. Had I been present, I would have voted ``yea'' on rollcall No. 272, H.R. 1606; and ``yea'' on rollcall No. 273, H.R. 3672. personal explanation
Mar 22, 2023
Are you looking at ways to redesign core features like the ones I mentioned to be less manipulative--excuse me--and addictive for users, and can you commit to making some of those modifications here today?
Apr 25, 2023
Last year, as you know, Congress finally--finally, after many, many decades, really--took the historic step of standing up to Big Pharma and enacting policies that are already--we are seeing it--lowering healthcare costs for millions of…
Other voices in this conversation
